Choongwae to transfer Imiphenem technology to Sandoz.

Imiphenem, a high value added antibiotic technology developed by a genuine Korean research team of Choongwae, seems to transfer to Sandoz, a subsidiary of Novartis and the 2nd largest generic drug company in the world.

The Imiphenem antibiotic technology was transferred to Sandoz at 9 p.m. on April 24 by signing the agreement between Chongwae and Novartis at the head office of Novartis in Ba...